NOVO NORDISK
Fri, 25 Jun 2021 12:02:00 -0400
Fri, 25 Jun 2021 12:02:00 -0400
For a third consecutive year, Novo Nordisk to award promising start-ups free space at Boston’s premier, biotech-capable shared lab facility
BOSTON, June 25, 2021 -- Wanted: high-potential life sciences and biotech start-up companies looking for an opportunity to be part of a vibrant innovation ecosystem where companies develop truly transformational science.
The Novo Nordisk Bio Innovation Hub issues an open call for promising start-up companies to submit non-confidential proposals for a Novo Nordisk-sponsored LabCentral “Golden Ticket”. The winner will have the chance to receive access for one scientist and one bench at LabCentral’s state-of-the-art shared lab space in Boston for one year. Novo Nordisk is committed to discovering, creating and co-creating innovation to solve healthcare challenges for people living with chronic diseases and will award two Golden Tickets a year for three years. To date, Novo Nordisk has sponsored four companies to take up residence at LabCentral and they continue to interact with the broader network of applicants.
Proposals should focus on technology or biology platforms, including computational and systems biology, artificial intelligence and machine learning and experimental cellular platforms. Proposals should have disease agnostic potential to identify novel drug targets. It is considered an advantage, but not a requirement, if the proposal can demonstrate a scientific connection or partnering academic team within one of Novo Nordisk’s therapeutic areas: diabetes, obesity, cardiovascular disease, NASH, chronic kidney disease, hemophilia and other rare blood disorders or rare endocrine disorders.
Life sciences start-ups interested in winning the LabCentral space should review the full competition terms and conditions to submit their “Golden Ticket” application via the competition website. Companies that meet the eligibility requirements must apply by Friday, August 6, 2021. A select number of companies will be invited to present their proposals to Novo Nordisk in September 2021.
LabCentral, just a short walk from Novo Nordisk’s Boston Innovation Hub in Kendall Square, and is a first-of-its-kind shared laboratory space located in the heart of Cambridge, Mass. It is designed as a launchpad for high-potential life sciences and biotech start-ups. Novo Nordisk has a long-standing scientific leadership in therapeutic and device innovation and established the Novo Nordisk Boston Innovation Hub to expand its US-based collaborations and partnerships. The Bio Innovation Hub team specifically focuses on co-creation initiatives.
Novo Nordisk A/S, a global healthcare company, organized and manages this “Golden Ticket” competition.
About Novo Nordisk
Novo Nordisk is a global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for 95 years. This heritage has given us experience and capabilities that also enable us to help people defeat other serious diseases including obesity, hemophilia and growth disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially and environmentally responsible way. With U.S. headquarters in New Jersey and production and research facilities in six states, Novo Nordisk employs nearly 6,000 people throughout the country. For more information, visit novonordisk.us , Facebook , Instagram , and Twitter .
About LabCentral
LabCentral provides fully equipped, permitted, and supported lab space for biomedical research, plus programming and unmatched networking opportunities to help start-ups advance their science and build their companies. It provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series – as well as the other critical services and support that start-ups need to begin laboratory operations on day one. A private, non-profit institution, LabCentral was funded in part by a $5 million grant from the Massachusetts Life Sciences Center, with support from its real estate partner, MIT.
Further information
| Media: |
|
|
| Michael Bachner | 609-664-7308 |
mzyb@novonordisk.com |